U.S. Multiple Sclerosis Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Immunomodulators, Immunosuppressants, Interferons, and Others), By Route of Administration (Oral and Injection {Intramuscular, Subcutaneous, and Intravenous}), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Forecast, 2023-2030

Last Updated: December 01, 2025 | Format: PDF | Report ID: FBI107918

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2030
Base Year	2022
Estimated Year	2023
Forecast Period	2023-2030
Historical Period	2019-2021
Growth Rate	CAGR of 5.9% from 2023-2030
Unit	Value (USD Billion)
Segmentation	By Drug Class, Route of Administration, and Distribution Channel
By Drug Class	Immunomodulators Immunosuppressants Interferons Others
By Route of Administration	Oral Injection Intramuscular Subcutaneous Intravenous
By End-user	Hospital Pharmacy Retail Pharmacy Online Pharmacy